ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Clinical trials for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS explained in plain language.
Never miss a new study
Get alerted when new ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS trials appear
Sign up with your email to follow new studies for ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
Could CAR-T cells tame autoimmune diseases? new trial launches
Disease control Recruiting nowThis study tests a new treatment called anti-CD19/BCMA universal CAR-T cells for people with severe autoimmune diseases like lupus, scleroderma, and rheumatoid arthritis that haven't responded to standard therapies. The treatment uses specially engineered immune cells to target a…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: EARLY_PHASE1 • Sponsor: Changhai Hospital • Aim: Disease control
Last updated May 26, 2026 03:17 UTC
-
Experimental cell therapy targets tough autoimmune cases
Disease control Recruiting nowThis early-stage study tests a new cell treatment called YTS109 in about 18 adults with autoimmune diseases like lupus or scleroderma that have not responded to standard therapies. Participants receive a single infusion of these modified immune cells. The main goal is to check sa…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:14 UTC
-
New cell therapy hopes to tame tough autoimmune diseases
Disease control Recruiting nowThis early-stage study is testing a new cell therapy called YTS109 in 18 adults with severe autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these specially designed immune cells. The m…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
New hope for vasculitis patients: experimental drug enters Mid-Stage trial
Disease control Recruiting nowThis study tests an experimental drug called tarperprumig in 75 adults with a rare autoimmune disease that inflames blood vessels (ANCA-associated vasculitis). The goal is to see if the drug is safe and can help control the disease, reducing flare-ups. Participants will receive e…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE2 • Sponsor: Alexion Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 26, 2026 03:11 UTC
-
Experimental cell therapy takes on lupus and other autoimmune diseases
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with hard-to-treat autoimmune diseases like lupus and Sjogren's syndrome. Participants receive a single infusion of these specially designed cells. The main goal is to see if the treatment is safe, and res…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 03:09 UTC
-
Experimental cell therapy targets tough autoimmune conditions
Disease control Recruiting nowThis early-stage study tests a new cell therapy called YTS109 in 18 adults with autoimmune diseases like lupus and Sjogren's syndrome that have not responded to standard treatments. Participants receive a single infusion of these immune cells to see if it is safe and can help con…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE1 • Sponsor: China Immunotech (Beijing) Biotechnology Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New hope for rare disease patients: study tests three rescue treatments for stubborn vasculitis
Disease control Recruiting nowThis study is for people with granulomatosis with polyangiitis, a rare disease where blood vessels get inflamed, who haven't improved with usual treatments. It compares three different drug combinations to see which works best to control the disease. About 42 adults will take par…
Matched conditions: ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated May 20, 2026 11:56 UTC